The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyridine benzamide and pyrazine benzamide compounds (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
                            本发明涉及治疗化合物领域,更具体地涉及某些
吡啶苯甲酰胺和
吡嗪苯甲酰胺化合物(以下简称P
DBA和
PZBA化合物),它们可以抑制蛋白激酶D(PKD)(例如PKD1、PKD2、PKD3)。本发明还涉及包含这些化合物的制药组合物,以及在体外和体内使用这些化合物和组合物来抑制PKD,在治疗由PKD介导、通过抑制PKD改善的疾病和病况,包括增生性疾病如癌症等。